Search - tctmd.com

Displaying 141 - 160 of 173

Sort: Relevancy | Date

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

Michael O'Riordan

May 30, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

Shelley Wood

April 28, 2017

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Daily News

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Michael O'Riordan

October 28, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

Advertisement

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

TCTMD’s Top 10 Most Popular Stories for April 2017

One in Five Acute MI Patients Drop Statins Within 2 Years

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content